Administration of omega-3 fatty acids and Raloxifene to women at high risk of breast cancer: Interim feasibility and biomarkers analysis from a clinical trial

European Journal of Clinical Nutrition

Volumn 66, Issue 8, 2012, Pages 878-884

  Signori, C ^a   Dubrock, C ^a   Richie, J P ^b   Prokopczyk, B ^b   Demers, L M ^c   Hamilton, C ^c   Hartman, T J ^c   Liao, J ^b   El Bayoumy, K ^b   Manni, A ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c Department of Pharmacology ^*  (United States)

Author keywords

breast cancer prevention; Lovaza; Raloxifene; serum and urine biomarkers; serum fatty acid composition

Indexed keywords

2 HYDROXYESTRONE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; ISOPROSTANE DERIVATIVE; OMEGA 3 ACID ETHYL ESTER; OMEGA 3 FATTY ACID; RALOXIFENE; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG TOLERABILITY; ESTROGEN METABOLISM; FATTY ACID ANALYSIS; FEMALE; HIGH RISK PATIENT; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; LEG CRAMP; NORMAL HUMAN; OXIDATIVE STRESS; PATIENT ATTITUDE; PHYSICAL ACTIVITY; POSTMENOPAUSE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; VAGINAL DRYNESS;

ADULT; AGED; BIOLOGICAL MARKERS; BREAST NEOPLASMS; C-REACTIVE PROTEIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDPOINT DETERMINATION; ESTROGEN ANTAGONISTS; FATTY ACIDS, OMEGA-3; FEASIBILITY STUDIES; FEMALE; FOOD HABITS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; LINEAR MODELS; LIPID PEROXIDATION; MIDDLE AGED; MOTOR ACTIVITY; OXIDATIVE STRESS; POSTMENOPAUSE; RALOXIFENE; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SIGNAL TRANSDUCTION;

EID: 84864854369     PISSN: 09543007     EISSN: 14765640     Source Type: Journal    
DOI: 10.1038/ejcn.2012.60     Document Type: Article

References (25)

1. Signori C, El-Bayoumy K, Russo J, Thompson HJ, Richie JP, Hartman TJ et a.l. Chemoprevention of breast cancer by fish oil in preclinical models: trials and tribulations. Cancer Res 2011; 71: 6091-6096.
2. Manni A, Xu H, Washington S, Aliaga C, Cooper T, Richie Jr JP et a.l. The impact of fish oil on the chemopreventive efficacy of tamoxifen against development of N-methyl-N-nitrosourea-induced rat mammary carcinogenesis. Cancer Prev Res 2010; 3: 322-330.
3. Manni A, Richie Jr JP, Xu H, Washington S, Aliaga C, Cooper TK et a.l. Effects of fish oil and Tamoxifen on preneoplastic lesion development and biomarkers of oxidative stress in the early stages of N-methyl-N-nitrosourea- induced rat mammary carcinogenesis. Int J Oncol 2011; 39: 1153-1164.
4. Manni A, Xu H, Washington S, Aliaga C, Das A, Cooper T et a.l. The effects of Tamoxifen and fish oil on mammary carcinogenesis in polyoma middle T transgenic mice. Horm Cancer 2011; 2: 249-259.
5. Boyd NF, Martin LJ, Rommens JM, Paterson AD, Minkin S, Yaffe MJ et a.l. Mammographic density: a heritable risk factor for breast cancer. Methods Mol Biol 2009; 472: 343-360.
6. Subar AF, Thompson FE, Kipnis V, Midthune D, Hurwitz P, McNutt S et a.l. Comparative validation of the Block, Willett, and National Cancer Institute food frequency questionnaires: the Eating at America's Table Study. Am J Epidemiol 2001; 154: 1089-1099. (Pubitemid 33140629)
7. Miller PE, Lazarus P, Lesko SM, Muscat JE, Harper G, Cross AJ et a.l. Diet indexbased and empirically derived dietary patterns are associated with colorectal cancer risk. J Nutr 2010; 140: 1267-1273.
8. Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE et a.l. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 2003; 35: 1381-1395. (Pubitemid 36936159)
9. Slot C. Plasma creatinine determination. A new and specific Jaffe reaction method. Scand J Clin Lab Invest 1965; 17: 381-387.
10. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM et a.l. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371-1388. (Pubitemid 28439961)
11. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN et a.l. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006; 295: 2727-2741.
12. Ropka ME, Keim J, Philbrick J.T. Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. J Clin Oncol 2010; 28: 3090-3095.
13. Waters EA, Cronin KA, Graubard BI, Han PK, Freedman A.N. Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women. Cancer Epidemiol Biomarkers Prev 2010; 19: 443-446.
14. Ruxton CH, Reed SC, Simpson MJ, Millington K.J. The health benefits of omega-3 polyunsaturated fatty acids: a review of the evidence. J Hum Nutr Diet 2007; 20: 275-285. (Pubitemid 46864278)
15. Yee LD, Lester JL, Cole RM, Richardson JR, Hsu JC, Li Y et a.l. Omega-3 fatty acid supplements in women at high risk of breast cancer have dose-dependent effects on breast adipose tissue fatty acid composition. Am J Clin Nutr 2010; 91: 1185-1194.
16. Harris W.S. n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997; 65(5 Suppl): 1645S-1654SS.
17. Skulas-Ray AC, Kris-Etherton PM, Harris WS, Vanden Heuvel JP, Wagner PR, West S.G. Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia. Am J Clin Nutr 2011; 93: 243-252.
18. Lee A.V. Y.D. Role of the IGF System. In Breast Cancer Proliferation and Progression, Manni A (ed). Humana Press, Inc.: Totowa, NJ, 1999.
19. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004; 363: 1346-1353. (Pubitemid 38529873)
20. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B et a.l. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 351: 1393-1396. (Pubitemid 28209997)
21. Torrisi R, Baglietto L, Johansson H, Veronesi G, Bonanni B, Guerrieri-Gonzaga A et a.l. Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer. Br J Cancer 2001; 85: 1838-1841. (Pubitemid 34775318)
22. Oleksik AM, Duong T, Pliester N, Asma G, Popp-Snijders C, Lips P. Effects of the selective estrogen receptor modulator, raloxifene, on the somatotropic axis and insulin-glucose homeostasis. J Clin Endocrinol Metab 2001; 86: 2763-2768. (Pubitemid 32545736)
23. Eliassen AH, Missmer SA, Tworoger SS, Hankinson S.E. Circulating 2-hydroxy-and 16alpha-hydroxy estrone levels and risk of breast cancer among postmenopausal women. Cancer Epidemiol Biomarkers Prev 2008; 17: 2029-2035.
24. Osborne MPKR, Hershcopf RJ, Bradlow HL, Kourides IA, Williams WR, Rosen PP et a.l. Omega-3 fatty acids: modulation of estrogen metabolism and potential for breast cancer prevention. Cancer Investigation 1988; 6: 629-631. (Pubitemid 19042670)
25. Rossner Jr P, Gammon MD, Terry MB, Agrawal M, Zhang FF, Teitelbaum SL et a.l. Relationship between urinary 15-F2t-isoprostane and 8-oxodeoxyguanosine levels and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2006; 15: 639-644.